Structural requirements of acetylcholinesterase reactivators.
about
Design, evaluation and structure-activity relationship studies of the AChE reactivators against organophosphorus pesticides.Relationships between the antidotal efficacy and structure, PK/PD parameters and bio-relevant molecular descriptors of AChE reactivating oximes: inclusion and integration to biopharmaceutical classification systems.Novel approaches to mitigating parathion toxicity: targeting cytochrome P450-mediated metabolism with menadione.SAR study to find optimal cholinesterase reactivator against organophosphorous nerve agents and pesticides.Sarin (GB, O-isopropyl methylphosphonofluoridate) neurotoxicity: critical review.Curious Cases of the Enzymes.In Vitro Comparison of Two Most Promising H-Oximes (HI-6 and HLö-7) and Currently Commercially Available Reactivators Pralidoxime and Obidoxime in Reactivation of Cyclosarin-Inhibited Human Cholinesterases.Potency of novel oximes to reactivate sarin inhibited human cholinesterases.The present approaches to the development of prophylactic and therapeutic antidotes against nerve agents.A comparison of the neuroprotective efficacy of newly developed oximes (K117, K127) and currently available oxime (obidoxime) in tabun-poisoned rats.Effect of seven newly synthesized and currently available oxime cholinesterase reactivators on cyclosarin-intoxicated rats.In vitro reactivation kinetics of paraoxon- and DFP-inhibited electric eel AChE using mono- and bis-pyridinium oximes.Amperometric Biosensors for Real Time Assays of Organophosphates.A comparison of reactivating and therapeutic efficacy of the oxime K203 and its fluorinated analog (KR-22836) with currently available oximes (obidoxime, trimedoxime, HI-6) against tabun in rats and mice.Effect of several new and currently available oxime cholinesterase reactivators on tabun-intoxicated rats.New K-Oximes (K-27 and K-48) in Comparison with Obidoxime (LuH-6), HI-6, Trimedoxime (TMB-4), and Pralidoxime (2-PAM): Survival in Rats Exposed IP to the Organophosphate Paraoxon.A comparison of reactivating and therapeutic efficacy of newly-developed oximes (K156, K203) and commonly used oximes (obidoxime, HI-6) in cyclosarin-poisoned rats and mice.In vitro oxime-assisted reactivation of paraoxon-inhibited human acetylcholinesterase and butyrylcholinesterase.A comparison of the reactivating and therapeutic efficacy of newly developed bispyridinium oximes (K250, K251) with commonly used oximes against tabun in rats and mice.A comparison of neuroprotective efficacy of newly developed oximes (K203, K206) and commonly used oximes (obidoxime, HI-6) in tabun-poisoned rats.In vitro reactivation of trichlorfon-inhibited butyrylcholinesterase using HI-6, obidoxime, pralidoxime and K048.Behavior of uncharged oximes compared to HI6 and 2-PAM in the human AChE-tabun conjugate: a molecular modeling approach.An evaluation of reactivating and therapeutic efficacy of newly developed oximes (K206, K269) and commonly used oximes (obidoxime, HI-6) in cyclosarin-poisoned rats and mice.Oxime-mediated in vitro reactivation kinetic analysis of organophosphates-inhibited human and electric eel acetylcholinesterase.A comparison of the potency of newly developed oximes (K074, K075) and currently available oximes (obidoxime, trimedoxime, HI-6) to counteract acute toxic effects of tabun and cyclosarin in mice.Oxime-dipeptides as anticholinesterase, reactivator of phosphonylated-serine of AChE catalytic triad: probing the mechanistic insight by MM-GBSA, dynamics simulations and DFT analysis.Targeted synthesis of 1-(4-hydroxyiminomethylpyridinium)-3-pyridiniumpropane dibromide--a new nerve agent reactivator.Two step synthesis of a non-symmetric acetylcholinesterase reactivator.Bisquaternary oximes as reactivators of tabun-inhibited human brain cholinesterases: an in vitro study.Potency of five structurally different acetylcholinesterase reactivators to reactivate human brain cholinesterases inhibited by cyclosarin.The Evaluation of the Reactivating and Neuroprotective Efficacy of Two Newly Prepared Bispyridinium Oximes (K305, K307) in Tabun-Poisoned Rats-A Comparison with Trimedoxime and the Oxime K203.A comparison of the reactivating and therapeutic efficacy of two novel bispyridinium oximes (K727, K733) with the oxime HI-6 and obidoxime in sarin-poisoned rats and mice.Potency of new structurally different oximes to reactivate cyclosarin-inhibited human brain acetylcholinesterases.New group of xylene linker-containing acetylcholinesterase reactivators as antidotes against the nerve agent cyclosarin.The evaluation of the reactivating and therapeutic efficacy of three novel bispyridinium oximes (K454, K456, K458) in comparison with the oxime K203 and trimedoxime in tabun-poisoned rats and mice.Effect of different oximes on rat and human cholinesterases inhibited by methamidophos: a comparative in vitro and in silico study.A comparison of the reactivating and therapeutic efficacy of two newly developed oximes (k727 and k733) with oxime k203 and trimedoxime in tabun-poisoned rats and mice.The evaluation of the reactivating and therapeutic efficacy of two novel oximes (K361 and K378) in comparison with the oxime K203 and trimedoxime in tabun-poisoned rats and mice.A newly developed oxime K203 is the most effective reactivator of tabun-inhibited acetylcholinesterase.Synthesis of a novel series of non-symmetrical bispyridinium compounds bearing a xylene linker and evaluation of their reactivation activity against tabun and paraoxon-inhibited acetylcholinesterase.
P2860
Q37660998-9134D7ED-E405-45B6-896A-5DCC1014FD9EQ38265360-A62F82BF-389D-4AA9-A129-63E61F6BEBA7Q38904010-ABE0869C-E1C4-4826-A4B6-1CD1DD9F9045Q38942948-D07EB1BA-D492-4834-A366-51E0AC5CBBBDQ38972692-E7B8D101-412A-4730-BD8B-1A4E5F796C02Q38990252-C45835A2-9E16-481B-9213-73DD703E63F4Q40139395-A8BAB713-B23F-4AF7-9676-CF8F5425CB28Q40140631-B92D8054-A0EE-4685-A826-96D8ADB252B3Q41451713-5DB3BDDB-B55E-4C2C-B41E-DE95B1BE141FQ41856128-977F7CAB-54C2-4F26-BF2C-DA5F898D6747Q42547753-5B629D84-623E-43F0-9B09-B904EBEF76ECQ42709237-7FE6CB64-2E03-4EAB-9928-94B50FD4C809Q43101146-35A53245-CD7D-4096-BAED-359FCFE2766CQ43127843-8F2095A1-B637-4595-993E-E090E743C8FFQ43187883-A0E1BE0F-2B83-4BB1-9019-D4598CAB32C9Q43215825-07B01E44-3AB6-4C18-9E3B-746BDED9B7C1Q43272003-6EA32CE5-5123-4C01-8D47-A65E050DDD07Q45935496-5755DB49-FCE4-4D3D-8FC6-460B408729F7Q45954928-B46D1B74-BF93-4F6B-9F73-64172A3DAB0FQ45974695-E407A102-1AF1-4590-9DFE-E4C8C3046E6BQ46339867-7B89824B-3346-4BE5-936E-B9A2C9EED4A7Q46376157-1F942601-8568-4CBA-8630-97447100F4E0Q46441344-C86BEFC6-0B91-4D80-A949-A628C742EAADQ46560113-7240E67E-9159-40EA-A931-161D10DB9E8EQ46831546-411242A5-803A-418D-A7D2-A5DF7F047D14Q46896783-E35C0737-FB6C-4F73-9277-1FAC91FE7333Q46932459-4D33D67A-56FE-4F76-9583-63B5A12A8E13Q46932491-6E2B5FAF-2B93-4409-B13C-7BE6B0C46F31Q48132308-D0326F0B-7531-4269-A994-A085E175E025Q48167739-08E57D35-4388-450B-84D9-31755F00CE5FQ48201397-A4A873E2-1313-4930-8311-EB1F0AF716EAQ48219915-E41A4459-471D-478A-936E-CF8EFFC66EF8Q48298070-8A2FE411-5A2A-473F-8D52-82AF67908CA3Q48325862-0E089E31-3DA9-4523-993E-5F8D0497D032Q48406291-64C90FF9-4AD7-4724-A156-61D3A643B951Q48471614-422460AF-65AF-403F-AB05-ABB29318E74EQ48539827-37C52511-1330-4B4D-BC2E-8277FE85C883Q48830524-A0E4024B-2754-4693-9F2D-946177C8DE8DQ50291735-6A9424EA-1677-412D-BFF0-FEAAF93A4E38Q52683914-B94E2BEE-6AF7-4C6B-B07F-E8191DA82582
P2860
Structural requirements of acetylcholinesterase reactivators.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Structural requirements of acetylcholinesterase reactivators.
@ast
Structural requirements of acetylcholinesterase reactivators.
@en
type
label
Structural requirements of acetylcholinesterase reactivators.
@ast
Structural requirements of acetylcholinesterase reactivators.
@en
prefLabel
Structural requirements of acetylcholinesterase reactivators.
@ast
Structural requirements of acetylcholinesterase reactivators.
@en
P1476
Structural requirements of acetylcholinesterase reactivators
@en
P2093
Daniel Juna
Kamil Kuca
P304
P356
10.2174/138955706776073510
P577
2006-03-01T00:00:00Z